VJOncology Podcast

Esophageal and gastric cancer highlights from ASCO GI 2024

In this podcast, we will discuss key insights from the 2024 ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco, CA. Topics include updates in the KEYNOTE-811, MATTERHORN, and CheckMate 649 trials, as well as the use of circulating free DNA analysis in esophagogastric cancer and the evolving landscape of treatment of HER2-positve metastatic gastric cancer. Additionally, hear on a pilot PET study using the positron-emitting agent 18F-BMS-986229 for PD-L1 imaging in advanced esophagogastric cancer and a retrospective investigation into the concordance between three PD-L1 scoring methods and their association with clinical outcomes in RATIONALE-302.

Tune in to hear perspectives from experts such as Yelena Y. Janjigian (Memorial Sloan Kettering Cancer Center, New York, NY), Samuel Louis Cytryn (Memorial Sloan Kettering Cancer Center, New York, NY), Kohei Shitara (National Cancer Center Hospital East, Kashiwa, Japan), Ken Kato (National Cancer Center Hospital, Tokyo, Japan) and Nataliya V. Uboha (University of Wisconsin Carbone Cancer Center, Madison, WI).

Key updates at ASCO GU 2024

In this podcast, we will discuss key insights from the 2024 ASCO Genitourinary (GU) Cancers Symposium held in San Francisco, CA. Topics include updates in the AMBASSADOR, CONTACT-2, and CLEAR trials, as well as why BCG-unresponsive patients with non-muscle invasive bladder cancer refuse cystectomy and the emerging role transperineal prostate biopsies. Tune in to hear perspectives from experts such as Andrea Apolo (National Institutes of Health, Bethesda, MD), Kim Chi (BC Cancer Vancouver Centre, Vancouver, Canada), Viktor Grünwald (University Hospital Essen, Essen, Germany), Joseph Jacob (Upstate Medical University, Syracuse, NY), and Jim Hu (Weill Cornell Medicine, New York, NY).

Highlights in bladder and prostate cancer at PROCSA/BLADDR 2023

In this podcast, we’ll be covering highlights from the PROCSA/BLADDR 2023 Meeting, which took place in Valencia, Spain, such as the evolution of targeted therapies and novel biomarker driven studies in prostate cancer, as well as trimodal therapy for non-muscle invasive bladder cancer. Hear from Rob Jones (The University of Glasgow, Glasgow, UK), Bertrand Tombal (Université catholique de Louvain, Ottignies-Louvain-la-Neuve, Belgium), Daniele Raggi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Bram De Laere (Ghent University, Ghent, Belgium), Paul Sargos (Institut Bergonié, Bordeaux, France), Felix Guerrero-Ramos (Hospital Universitario 12 de Octubre, Madrid, Spain), Eva Compérat (Medical University of Vienna, Vienna, Austria). 

Key updates at ESMO Asia 2023

The recent European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore, brought together key oncology experts to delve into the latest oncology advancements. In this podcast episode, we are honored to host discussions with distinguished guests: Enrique Grande (MD Anderson Cancer Centre Madrid, Madrid, Spain), Molly Li (Queen Elizabeth Hospital, Hong Kong), Karijn Suijkerbuijk (UMC Utrecht, Utrecht, The Netherlands), and Hidehito Horinouchi (National Cancer Center Hospital, Tokyo, Japan).

The conversation will provide insights into noteworthy perspectives on cellular therapy development in Asia, the use of immunotherapies for advanced acral and mucosal melanoma, novel ADCs in EGFR-mutant lung cancer and a potential new standard of care in urothelial cancer.

Breast Cancer Sessions: Highlights from SABCS 2023 with Sara Tolaney, Sarah Sammons & Paolo Tarantino

The San Antonio Breast Cancer Symposium (SABCS) 2023 took place on the 5-9th of December 2023 in San Antonio, TX. Leading experts in breast cancer came together to hear the latest clinical trial data and discuss how to improve care for patients with breast cancer.

In this podcast, we hear from Sara Tolaney, MD, MPH, Sarah Sammons, MD, and Paolo Tarantino, MD, of Dana-Farber Cancer Institute, Boston, MA, as they discuss the hot topics from SABCS 2023 in an exclusive roundtable discussion. Topics covered include updates on the management of HR+/HER2- breast cancer such as the role of CDK4/6 inhibitors as evaluated in MONARCH 3 (NCT02246621) and PARSIFAL (NCT02491983), the potential of PIK3CA described in the INAVO120 trial (NCT04191499), the use of ribociclib and endocrine therapy as adjuvant treatment in HR+/HER2- early breast cancer, and finally neoadjuvant immunotherapy in HR-positive early breast cancer.

Updates in GI cancer at ESMO 2023

The European Society for Medical Oncology (ESMO) Congress 2023 brought together leading experts to explore and deliberate on the most recent advancements and breakthroughs in the field of oncology. In this podcast, joining us will be John H. Strickler (Duke Cancer Institute, Durham, NC), Stephen L. Chan (The Chinese University of Hong Kong, Hong Kong, China), Benedikt Westphalen (Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany), Filippo Pietrantonio (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Yoshiaki Nakamura (National Cancer Center Hospital East, Kashiwa, Japan) and Lorenza Rimassa (Humanitas University, Milan, Italy).

Discussions cover updates from various trials, emphasizing the effectiveness of tucatinib plus trastuzumab in HER2-positive RAS-WT metastatic colorectal cancer (mCRC) in the MOUNTAINEER (NCT03043313) trial and sotorasib with panitumumab in KRAS G12C mCRC in the CodeBreak 300 trial. Trials in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) trials are highlighted and data on ctDNA as a prognostic biomarker in resected CRC is discussed, as well as prognostic factors contributing to long-term survivorship in patients with hepatobiliary cancers and advances in targeting KRAS in GI malignancies.

2023 updates in metastatic colorectal cancer genomic biomarkers

Huge advancements in personalized medicine and the availability of genetic testing have led us to consider the use of genomic alterations as biomarkers in cancer treatment. In this podcast, we will revisit the most recent developments in the efficacy and clinical application of genomic biomarkers in metastatic colorectal cancer (mCRC) presented during 2023.

We will hear from Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, regarding the CodeBreak 300 trial (NCT05198934); John H. Strickler, MD, Duke Cancer Institute, Durham, NC, on MOUNTAINEER (NCT03043313); Ardaman Shergill, MD University of Chicago, Chicago, IL, on PARADIGM (NCT02394795), STRATEGIC-1 (NCT01910610) and CAIRO5 (NCT02162563) and Benny Johnson, DO, The University of Texas MD Anderson Cancer Center, Houston, TX, who rounds off the discussion by considering the use of circulating tumor DNA (ctDNA) to assess minimal residual disease (MRD) status.

Be sure to visit our dedicated page on genomic biomarkers in metastatic colorectal cancer here to learn more about current and future biomarker testing standards, as well as potential treatment directions in the future.

Highlights in cancer nursing at UKONS 2023

The 2023 UK Oncology Nursing Society (UKONS) meeting, which took place in Newport, Wales, gathered leading oncology experts to discuss the latest developments in cancer nursing. In this podcast, we will be joined by Verna Lavender, PhD (Guy's and St Thomas'​ NHS Foundation Trust, London, UK), Gina Madera (The Christie NHS Foundation Trust, Manchester, UK), and Sarah Adomah (The Royal Marsden NHS Foundation Trust, London, UK).

We will hear on updates on important initiatives and programs such as the Creation of Acute oncology Standardized Competence Assessment Documents and their Evaluation (CASCADE) project and Aspirant Cancer Career and Education Development (ACCEND) program, which both aim to enhance cancer education in the UK.

Highlights in gynecologic cancer from ESMO 2023

The European Society for Medical Oncology (ESMO) Congress 2023 gathered prominent experts to discuss the latest research and breakthroughs in oncology. In this podcast, joining us will be Mary McCormack (UCL Hospitals NHS Foundation Trust, London, UK), Benoit You (Lyon University Hospital, Lyon, France), Domenica Lorusso (Fondazione IRCCS National Cancer Institute of Milan, Italy), Mansoor Raza Mizra (Copenhagen University Hospital, Denmark) and Shannon N. Westin (MD Anderson Cancer Center, Houston, TX). 

Updates from multiple trials are discussed, highlighting the efficacy of induction chemotherapy plus chemoradiation in the INTERLACE trial, the combination of pembrolizumab with chemoradiation in the KEYNOTE-A18 trial (NCT04221945), and the potential of tisotumab vedotin in the innovaTV 301 trial (NCT04697628)—all focusing on advanced cervical cancer. Additionally, discussions cover the RUBY (NCT03981796) and DUO-E (NCT04269200) trials exploring the use of various immunotherapy agents combined with chemotherapy for the treatment of advanced endometrial cancer.

Highlights in breast cancer from ESMO 2023

The European Society for Medical Oncology (ESMO) Congress 2023, which took place in Madrid, Spain, gathered internationally acclaimed experts to share and deliberate on the most recent breakthroughs in oncology. In this podcast, we listen to prominent healthcare professionals offering a summary of key moments from this year’s conference.

Today we are joined by Peter Schmid (Barts Cancer Institute, London, UK), Erika Hamilton (Sarah Cannon Research Institute, Nashville, TN), Kevin Kalinsky (Emory University Hospital, Atlanta, GA), and Sherene Loi (Peter MacCallum Cancer Centre, Victoria, Australia), who share key updates in breast cancer at ESMO 2023. Topics discussed include findings from the BEGONIA (NCT03742102), KEYNOTE-522 (NCT03036488), CheckMate7FL trials (NCT04109066), novel estrogen receptor degraders vepdegestrant, as well the current state of CDK4/6 inhibitors in metastatic HER2-negative breast cancer.